SNSW(SH:688117) Zhong Zheng Wang·2025-08-15 06:21Core Viewpoint - The company reported significant growth in revenue and net profit for the first half of 2025, driven primarily by increased overseas sales of GLP-1 raw materials, specifically semaglutide and teriparatide [1][2]. Financial Performance - The company achieved operating revenue of 338 million yuan, a year-on-year increase of 69.69% [1] - Net profit attributable to shareholders reached 88.96 million yuan, up 308.29% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 89.48 million yuan, reflecting a 367.92% increase [1] - Basic earnings per share were 0.57 yuan [1] - Net cash flow from operating activities was 81.66 million yuan, a 213.22% increase year-on-year [1] - Sales expenses decreased by 32.18% due to price adjustments in acetic acid octreotide injection [1] Market Expansion and R&D - The company made significant strides in expanding its overseas market, building a business development team, and optimizing product layouts in regions such as the US, EU, South Korea, and Russia [2] - The efficiency of R&D output improved, with semaglutide raw materials certified by the Korean FDA and other products receiving drug registration certificates [2] - The company is providing CDMO services for innovative peptide drugs, with a diabetes and obesity project entering clinical phase III [2] Production Capacity and Strategy - The company successfully launched a new production line for peptide raw materials with an annual capacity of 395 kg [2] - Ongoing projects are expected to enhance production capacity to meet increasing customer orders [2] - The company plans to focus on the peptide pharmaceutical industry, emphasizing R&D innovation and internationalization, while expanding its market presence in diabetes, obesity, and other significant disease areas [3]